Article Figures & Data
Tables
- Table 1.
Recommended advanced treatment for patients with diabetes, identified by grade of evidence
TREATMENT ESTABLISHED DISEASE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE CHRONIC KIDNEY DISEASE HEART FAILURE RISK FACTORS* OUTCOME OUTCOME OUTCOME OUTCOME MACE HHF NEPHRO MACE HHF NEPHRO MACE HHF NEPHRO MACE HHF NEPHRO SGLT2I • Empagliflozin A B B C A A A • Canagliflozin B B B B A A A B C • Dapagliflozin B B A A A B C GLP1-RA • Semaglutide
SCB B C • Liraglutide A B B • Dulaglutide A A GLP1-RA—glucagonlike peptide-1 receptor agonist, HHF—hospitalization for heart failure, MACE—major cardiovascular event, NEPHRO—progression of nephropathy, SC—subcutaneous, SGLT2I—sodium-glucose co-transporter-2 inhibitor.
↵*Risk factors include smoking, hypertension, dyslipidemia, and central obesity.
Recommendations from Diabetes Canada1 and the American Diabetes Association.2
